Anaphylaxis Clinical Trial
Official title:
PEAnut Anaphylaxis Predictors
Peanut allergy can be life-threatening. Current diagnostic techniques for peanut allergy have high sensitivity, but not high specificity. This clinical trial will test the validity of a novel blood biomarker (compared with current testing) as a diagnostic predictor of anaphylaxis to peanut.
Children aged 2-17 years with suspected peanut allergy will be invited to participate in the
study.
They will have a questionnaire, a skin prick test to peanut, 2 breathing tests (spirometry
and fraction of exhaled nitric oxide (FeNO)), and a blood test (specific peanut antibodies,
allergic immune responses - including the novel blood biomarker - and genetic testing to
identify novel potential molecular and genetic markers of food allergy in the future. The
genetic testing component will be optional). The breathing test is not required for those
under 6 years.
The final step is an open label peanut food challenge with incremental doses of peanut,
(routine practise) as per the Australasian Society of Clinical Immunology and Allergy (ASCIA)
food challenge protocol.The endpoints in the food challenge will be signs of allergy or
anaphylaxis as per PRACTicing ALLergology (PRACTALL) consensus report for oral food
challenges OR completion of the ASCIA food challenge protocol.
Outcome: The primary outcome of the project is to confirm that a novel blood biomarker has a
higher diagnostic accuracy as compared to current best testing in predicting anaphylaxis at
open label peanut challenge.
Secondary outcome: Will be to determine the value of the biomarker, FeNO and Ara h2 specific
Immunoglobulin E (sIgE) (individually and in combination) at predicting anaphylaxis or
clinical allergy at open label peanut challenge.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04475003 -
Health Literacy Among Caregivers of Children With IgE-mediated Allergy With Risk of Anaphylaxis
|
||
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Completed |
NCT00047918 -
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
|
N/A | |
Active, not recruiting |
NCT03953482 -
Evaluation of Medical Care and Patient's Knowledge About the Behavior to Take on Secondary Prevention of Anaphylaxis
|
||
Recruiting |
NCT05112367 -
Epidemiology and Management of Pediatric Anaphylaxis and Allergy in the Pediatric Emergency Department of Montpellier
|
||
Completed |
NCT03366298 -
Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers
|
Phase 4 | |
Completed |
NCT02958605 -
Smartphone Apps for Pediatric Resuscitation
|
N/A | |
Completed |
NCT04696822 -
Bioavailability of Nasal Epinephrine
|
Phase 1 | |
Completed |
NCT03942692 -
What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
|
||
Completed |
NCT02854969 -
Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device
|
N/A | |
Completed |
NCT03282929 -
Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)
|
Phase 1 | |
Recruiting |
NCT01326741 -
Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis
|
N/A | |
Recruiting |
NCT06445374 -
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges
|
Phase 1 | |
Completed |
NCT01217138 -
Make up for the Epinephrine Autoinjector
|
Phase 4 | |
Completed |
NCT01432522 -
A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine
|
N/A | |
Completed |
NCT02028065 -
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
|
Phase 1 | |
Active, not recruiting |
NCT01247415 -
Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine
|
N/A | |
Completed |
NCT00868842 -
Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis
|
N/A | |
Completed |
NCT04290507 -
Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit
|